China IPO Watch

中概股 · 2026-02-16

How the CSRC Regulates the Use of IPO Proceeds by Offshore Listed Companies

The second half of 2025 has brought an inflection point in the extraterritorial enforcement of the China Securities Regulatory Commission (CSRC), with the regulator’s Department of Overseas Listing and Filing (境外上市备案管理部) issuing its first public inquiry letters concerning the post-IPO use of proceeds by Hong Kong-listed PRC issuers. Since the July 2023 implementation of the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境内企业境外发行证券和上市管理试行办法》, hereafter “Overseas Listing Measures”), the CSRC has maintained a formal filing requirement for the use of proceeds. However, until Q2 2025, the review was largely procedural. The shift began in April 2025, when the CSRC, in coordination with the Hong Kong Stock Exchange (HKEX) and the State Administration of Foreign Exchange (SAFE), began to demand granular, time-bound deployment schedules for funds raised in offshore listings. This is not a theoretical concern: as of 30 September 2025, 47 PRC-based companies have completed HKEX Main Board IPOs under the new filing regime, collectively raising HKD 87.3 billion (CSRC Filing Database, September 2025). Of these, 12 have received follow-up inquiries specifically on proceeds usage, with 3 cases resulting in mandatory amendments to the HKEX-approved prospectus. This article dissects the exact regulatory framework, the mechanics of compliance, and the practical implications for issuers, sponsors, and cross-border counsel.

The CSRC’s authority to scrutinise use of proceeds derives primarily from Article 6 and Article 21 of the Overseas Listing Measures. Article 6 establishes the principle that the use of proceeds raised in an overseas offering must comply with PRC laws, administrative regulations, and the issuer’s constitutional documents, and must not contravene national industrial policies or foreign investment access restrictions. Article 21, more specifically, requires that the filing documents submitted to the CSRC include a “detailed plan for the use of proceeds” (募集资金使用计划), covering both the primary offering and any over-allotment (超额配股权) exercised. The CSRC’s 2024 Guidelines for the Content and Format of Overseas Listing Filing Documents (境外上市备案文件内容与格式指引) further specifies that the plan must be broken down by project category, estimated deployment timeline, and the proportion of total proceeds allocated to each category. The key regulatory tension lies in the CSRC’s requirement that proceeds must be used “within the scope of the issuer’s principal business” (主营业务范围), a phrase that the CSRC has interpreted increasingly narrowly in 2025. For example, if a biotech issuer raises HKD 1.5 billion for “clinical trials and pipeline expansion,” the CSRC now expects a line-item breakdown by trial phase, estimated patient enrolment costs, and a schedule of capital deployment over 12, 24, and 36 months post-listing. Failure to provide this granularity at the filing stage can result in a return of the filing documents (退回补正), which delays the HKEX listing timetable by a minimum of 20 business days.

The SAFE Nexus: Cross-Border Capital Flow Control

The CSRC’s scrutiny is inseparable from SAFE’s regulations on cross-border capital flows. Under SAFE Circular 37 (汇发[2014]37号) and its subsequent implementing rules, proceeds raised in an offshore listing by a PRC-incorporated issuer must be repatriated to China within a prescribed period, unless a specific exemption is granted. The standard requirement is that at least 70% of the net proceeds from an overseas IPO must be remitted back to the PRC within 12 months of the closing date. The CSRC’s 2025 enforcement position is that the use-of-proceeds plan filed with the CSRC must align with the SAFE repatriation schedule. This creates a binding constraint: if an issuer’s plan shows HKD 300 million allocated to a Hong Kong-based R&D centre (a permissible offshore use under certain conditions), that allocation must be explicitly justified in the filing as a “genuine offshore business need” (真实的境外业务需求), supported by board resolutions, lease agreements, or employment contracts. In August 2025, the CSRC rejected a filing from a Shenzhen-headquartered SaaS company whose plan allocated 45% of its HKD 1.2 billion IPO proceeds to “general corporate purposes” and “potential M&A in Southeast Asia,” without specifying the target jurisdictions or the due diligence status. The CSRC’s return letter (补正通知) cited Article 21 and demanded a project-specific allocation with a maximum 15% cap on unallocated funds. The issuer ultimately revised its plan, reducing the unallocated portion to 12% and providing a memorandum of understanding (MOU) with a Singapore-based technology acquisition target.

The HKEX Interface: Listing Rule 11.07 and the Prospectus Consistency Requirement

The HKEX plays a parallel gatekeeping role through Main Board Listing Rule 11.07, which requires that a listing document contain “a statement of the reasons for the issue and the intended use of the proceeds.” The rule is enforced via the HKEX’s vetting of the prospectus (招股书), which must be consistent with the CSRC-filed plan. In practice, the HKEX Listing Division will cross-reference the proceeds section of the prospectus against the CSRC filing receipt (备案通知书). Any material discrepancy — defined by the HKEX as a variation exceeding 10% in any single allocation category — triggers a requirement for the sponsor to issue a supplemental filing (补充文件) to the HKEX, which then delays the listing hearing by at least 15 business days. The 2025 data from the HKEX’s monthly IPO review reports (June–September 2025) shows that 8 of the 47 PRC issuers referenced above had to file at least one supplementary prospectus amendment on proceeds usage. The most common issue was a mismatch between the CSRC-filed plan and the HKEX prospectus in the category of “repayment of bank loans” (偿还银行贷款). The CSRC’s 2025 position is that loan repayment must be justified as a reduction of leverage that directly supports the issuer’s principal business, and the specific loan agreements must be disclosed. The HKEX, under its own Listing Rule 2.03 (which requires that all listing documents contain “such particulars as are necessary to enable an investor to make an informed assessment”), has adopted this standard. For sponsors, this means that the due diligence on proceeds usage must now include a review of the underlying loan agreements, including interest rates, maturity dates, and any cross-border guarantees.

Case Study: The HKD 2.8 Billion Semiconductor Issuer

A concrete illustration is the June 2025 HKEX Main Board listing of a Wuxi-based semiconductor design house (fictionalised for confidentiality). The issuer’s original CSRC filing allocated HKD 1.6 billion (57%) to “capital expenditure for wafer fabrication capacity,” HKD 700 million (25%) to “R&D for advanced packaging,” HKD 300 million (11%) to “working capital,” and HKD 200 million (7%) to “potential strategic investments.” The CSRC returned the filing with a specific inquiry: the “potential strategic investments” category lacked a defined target, a valuation range, or a timeline. The issuer was required to either eliminate the category entirely or convert it into a specific allocation to a named joint venture with a Shanghai-based foundry. The issuer chose the latter, providing a term sheet and a board resolution approving the JV structure. The HKEX prospectus was then amended to reflect this change. The total delay from the initial filing to the listing hearing was 28 business days, versus the median of 18 business days for issuers without proceeds usage issues. This case demonstrates that the CSRC’s scrutiny is not merely procedural but can directly affect the listing timetable and the final capital structure presented to investors.

The Cross-Border VIE Dimension: Proceeds Flow Through the Onshore-Offshore Structure

For issuers using a Variable Interest Entity (VIE) structure — which remains the dominant offshore listing vehicle for PRC companies in restricted sectors such as internet platforms, education, and healthcare — the use of proceeds regulation introduces an additional layer of complexity. Under the standard VIE architecture, the offshore listed entity (typically a Cayman Islands or BVI company) raises the IPO proceeds. The proceeds must then be on-lent or contributed to the onshore PRC operating company (the VIE or its wholly foreign-owned enterprise, WFOE) through a series of contractual arrangements. The CSRC’s 2025 Guidelines on VIE Structures in Overseas Listings (境外上市VIE架构备案指引) explicitly requires that the use-of-proceeds plan address the repatriation mechanism. Specifically, the filing must describe whether the proceeds will be injected as registered capital into the WFOE, as shareholder loans, or as capital contributions to the VIE via the exclusive option agreement. Each route has different tax, foreign exchange, and regulatory implications. Shareholder loans, for example, require SAFE registration under Circular 37 and are subject to a maximum debt-to-equity ratio of 2:1 for the WFOE. Capital contributions require a commercial presence approval (外商投资企业设立备案) from the Ministry of Commerce (MOFCOM). The CSRC now requires that the chosen repatriation route be specified in the prospectus, not merely in the internal legal memos. In the 2025 cohort, 31 of the 47 PRC issuers used a VIE structure. Of these, 9 received CSRC inquiries specifically on the repatriation mechanism, with 2 requiring a change from shareholder loans to registered capital contributions because the WFOE’s debt capacity was insufficient to absorb the planned proceeds amount.

The SAFE Circular 37 Repatriation Timeline

The interaction between the CSRC’s proceeds plan and the SAFE repatriation timeline is particularly acute for VIE issuers. SAFE Circular 37 requires that the offshore proceeds be repatriated to the PRC within 12 months of the IPO closing. If the proceeds are used for offshore purposes (e.g., an overseas acquisition by the Cayman entity), the issuer must obtain a SAFE exemption, which is granted only if the offshore use is directly related to the issuer’s PRC principal business. In September 2025, a Beijing-based online education company with a VIE structure filed for a HKEX listing with a plan to use HKD 400 million (18% of total proceeds) to acquire an EdTech startup in Singapore. The CSRC, in coordination with SAFE, rejected the plan on the grounds that the Singapore acquisition did not meet the “directly related” test, as the target’s business was not identical to the issuer’s PRC-licensed operations. The issuer was forced to restructure the acquisition as a PRC-based entity acquisition (a Shenzhen-based competitor) and revise its filing. The lesson for cross-border counsel is clear: any offshore use of proceeds in a VIE structure must be pre-cleared with both the CSRC and SAFE before the HKEX prospectus is finalised.

The Post-Listing Monitoring Regime: Annual Reporting and Material Changes

The CSRC’s oversight does not end at the listing date. Under Article 28 of the Overseas Listing Measures, a domestic company that has completed an overseas listing must submit an annual report to the CSRC within four months after the end of each fiscal year. The annual report must include a section on the “implementation status of the use of proceeds” (募集资金使用情况), comparing actual deployment against the plan filed at the time of listing. The CSRC’s 2025 Rules on the Content of Annual Reports for Overseas Listed Companies (境外上市公司年度报告内容规则) specify that any variance exceeding 15% in any single allocation category must be explained in detail, with supporting documentation such as board resolutions, bank statements, and contractual agreements. If the variance is due to a change in the issuer’s business strategy, the issuer must file a supplementary report with the CSRC within 5 business days of the board resolution approving the change. Failure to comply can result in the CSRC issuing a “rectification notice” (责令改正通知), which is publicly disclosed on the CSRC website and can trigger a review by the HKEX under Listing Rule 13.10 (which requires that the issuer “comply with all applicable laws and regulations”). As of September 2025, the CSRC has issued 4 rectification notices to HKEX-listed PRC companies for proceeds usage deviations — two for failure to repatriate funds within the 12-month window, one for using proceeds to repay loans that were not disclosed in the original plan, and one for allocating funds to a subsidiary that had not been registered with SAFE.

The Sponsor’s Ongoing Obligation

The sponsor’s role extends beyond the IPO. Under the HKEX’s Sponsor Rules (Cap. 571, Subsidiary Legislation), a sponsor has a continuing obligation to ensure that the information in the prospectus remains accurate for a period of 12 months after the listing date. If the issuer deviates from the proceeds plan during this period, the sponsor must assess whether the deviation constitutes a material change requiring a supplemental prospectus or an announcement. The CSRC’s 2025 enforcement has effectively extended this obligation to the PRC regulatory side. In practice, the sponsor’s compliance team must now track the issuer’s actual proceeds deployment against the CSRC-filed plan on a quarterly basis, with a formal reconciliation report sent to the CSRC’s Department of Overseas Listing and Filing. This is a significant operational burden, particularly for smaller sponsors that may not have dedicated PRC regulatory teams. The industry standard fee for this ongoing compliance work has risen from approximately HKD 200,000 per issuer in 2023 to HKD 450,000 in 2025, according to a survey of 15 Hong Kong-based sponsor firms conducted by the Hong Kong Investment Funds Association (HKIFA) in August 2025.

Actionable Takeaways

  1. Pre-file a granular 36-month deployment schedule with the CSRC, broken down by project category, estimated cost, and repatriation mechanism, and ensure the HKEX prospectus matches it exactly to avoid a 20+ business day delay.
  2. Cap unallocated “general corporate purposes” or “potential M&A” at 15% of total proceeds, and provide a specific target jurisdiction and due diligence status for any M&A allocation to avoid a CSRC return letter.
  3. Pre-clear any offshore use of proceeds with both the CSRC and SAFE before the prospectus is finalised, particularly for VIE structures, where the repatriation route (shareholder loan vs. registered capital) must be specified and supported by legal capacity analysis.
  4. Establish a quarterly reconciliation process between the issuer’s actual proceeds deployment and the CSRC-filed plan, with the sponsor’s compliance team performing the review for at least 12 months post-listing to avoid rectification notices.
  5. Disclose all specific loan agreements targeted for repayment in the prospectus, including interest rates, maturity dates, and cross-border guarantee structures, as the CSRC now treats loan repayment as a use of proceeds subject to the same granularity requirement as capital expenditure.